Trial Profile
Examining Oncolytic Poliovirus Bioactivity in Tumor Tissue After Intratumoral Administration of PVSRIPO in Women With Invasive Breast Cancer
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Lerapolturev (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Triple negative breast cancer
- Focus Pharmacodynamics
- Sponsors Istari Oncology
- 04 Aug 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 04 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2022.
- 15 Mar 2019 Planned initiation date changed from (estimated date for recruitment of the first subject) 24 Sep 2018 to 15 Apr 2019.